HRP20180943T1 - Pročišćavanje protutijela preko kromatografije kationske izmjene - Google Patents
Pročišćavanje protutijela preko kromatografije kationske izmjene Download PDFInfo
- Publication number
- HRP20180943T1 HRP20180943T1 HRP20180943TT HRP20180943T HRP20180943T1 HR P20180943 T1 HRP20180943 T1 HR P20180943T1 HR P20180943T T HRP20180943T T HR P20180943TT HR P20180943 T HRP20180943 T HR P20180943T HR P20180943 T1 HRP20180943 T1 HR P20180943T1
- Authority
- HR
- Croatia
- Prior art keywords
- mes
- nacl
- value
- cation exchange
- exchange chromatography
- Prior art date
Links
- 238000011091 antibody purification Methods 0.000 title 1
- 238000005277 cation exchange chromatography Methods 0.000 title 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 18
- 239000011780 sodium chloride Substances 0.000 claims 9
- 239000011534 wash buffer Substances 0.000 claims 6
- 239000007993 MOPS buffer Substances 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 239000012149 elution buffer Substances 0.000 claims 3
- 239000006167 equilibration buffer Substances 0.000 claims 3
- 238000000746 purification Methods 0.000 claims 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Claims (3)
1. Uporaba, naznačena time, da se upotrebljava
ekvilibracijski pufer koji obuhvaća 13 do 33 mM MES i 50 do 70 mM NaCl, uz vrijednost pH od 5,1 do 5,9,
prvi pufer za ispiranje koji obuhvaća 15 do 35 mM MOPS uz vrijednost pH od 6,6 do 7,4,
drugi pufer za ispiranje koji obuhvaća 13 do 33 mM MES i 5 do 20 mM NaCl, uz vrijednost pH od 5,1 do 5,9, i
eluacijski pufer koji obuhvaća 13 do 33 mM MES i 160 do 190 NaCl, uz vrijednost pH od 5,4 do 5,6,
za pročišćavanje Bevacizumaba.
2. Uporaba prema zahtjevu 1, naznačena time, da se nadalje upotrebljava
ekvilibracijski pufer koji obuhvaća 23 mM MES i 60 mM NaCl, uz vrijednost pH od 5,5 i uz provodljivost od 6,9 mS/cm,
prvi pufer za ispiranje koji obuhvaća 25 mM MOPS uz vrijednost pH od 7,0,
drugi pufer za ispiranje koji obuhvaća 23 mM MES i 10 mM NaCl, uz vrijednost pH od 5,5 i uz provodljivost od 1,5 mS/cm, i
eluacijski pufer koji obuhvaća 23 mM MES i 175 mM NaCl, uz vrijednost pH od 5,5 i uz provodljivost od 18 mS/cm,
za pročišćavanje Bevacizumaba.
3. Uporaba prema zahtjevu 1, naznačena time, da se nadalje upotrebljava
ekvilibracijski pufer koji obuhvaća 23 mM MES i 60 mM NaCl, uz vrijednost pH od 5,4 do 5,6 i uz provodljivost od 6,1 do 7,7 mS/cm,
prvi pufer za ispiranje koji obuhvaća 25 mM MOPS uz vrijednost pH od 6,9 do 7,1 i uz provodljivost od 0,2 do 1,2 mS/cm,
drugi pufer za ispiranje koji obuhvaća 23 mM MES i 10 mM NaCl, uz vrijednost pH od 5,4 do 5,6 i uz provodljivost od 1,2 do 1,8 mS/cm, i
eluacijski pufer koji obuhvaća 23 mM MES i 175 mM NaCl, uz vrijednost pH od 5,45 do 5,55 i uz provodljivost od 17,5 do 18,5 mS/cm,
za pročišćavanje Bevacizumaba.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98382507P | 2007-10-30 | 2007-10-30 | |
| EP14189095.4A EP2840090B1 (en) | 2007-10-30 | 2008-10-29 | Antibody purification by cation exchange chromatography |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180943T1 true HRP20180943T1 (hr) | 2018-08-10 |
Family
ID=40262967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150282TT HRP20150282T4 (hr) | 2007-10-30 | 2015-03-12 | Purifikacija protutijela pomoću kromatografije kationskom izmjenom |
| HRP20180943TT HRP20180943T1 (hr) | 2007-10-30 | 2018-06-18 | Pročišćavanje protutijela preko kromatografije kationske izmjene |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150282TT HRP20150282T4 (hr) | 2007-10-30 | 2015-03-12 | Purifikacija protutijela pomoću kromatografije kationskom izmjenom |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20090148435A1 (hr) |
| EP (4) | EP2215117B2 (hr) |
| JP (5) | JP5237382B2 (hr) |
| KR (3) | KR20150008503A (hr) |
| CN (3) | CN105315323A (hr) |
| AR (2) | AR069097A1 (hr) |
| AU (1) | AU2008318865B2 (hr) |
| BR (1) | BRPI0817182A2 (hr) |
| CA (1) | CA2703279C (hr) |
| CL (1) | CL2008003218A1 (hr) |
| CO (1) | CO6280422A2 (hr) |
| CY (1) | CY1116129T1 (hr) |
| DK (3) | DK2565206T3 (hr) |
| ES (3) | ES2533266T5 (hr) |
| HK (4) | HK1182401A1 (hr) |
| HR (2) | HRP20150282T4 (hr) |
| HU (3) | HUE024877T2 (hr) |
| IL (4) | IL205310A0 (hr) |
| ME (1) | ME02101B (hr) |
| MX (1) | MX2010004740A (hr) |
| NZ (1) | NZ584839A (hr) |
| PE (1) | PE20091434A1 (hr) |
| PH (1) | PH12013501128A1 (hr) |
| PL (3) | PL2840090T3 (hr) |
| PT (1) | PT2215117E (hr) |
| RS (1) | RS53850B2 (hr) |
| RU (1) | RU2498991C2 (hr) |
| SG (2) | SG175597A1 (hr) |
| SI (3) | SI2215117T2 (hr) |
| TW (2) | TWI554517B (hr) |
| WO (1) | WO2009058812A1 (hr) |
| ZA (2) | ZA201002850B (hr) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101220691B1 (ko) | 2003-11-05 | 2013-01-14 | 로슈 글리카트 아게 | 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진ｃｄ20 항체 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006078307A1 (en) * | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| BRPI0606542A8 (pt) | 2005-02-23 | 2018-03-20 | Genentech Inc | métodos para aumentar o tempo de progressão de uma doença (ttp) |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| CN103397065A (zh) | 2006-09-13 | 2013-11-20 | 雅培制药有限公司 | 细胞培养改良 |
| ES2477497T3 (es) | 2007-03-02 | 2014-07-17 | Genentech, Inc. | Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo |
| BRPI0817182A2 (pt) * | 2007-10-30 | 2015-03-17 | Genentech Inc | Método para purificar um anticorpo e composições |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| EP2346897A2 (en) | 2008-10-20 | 2011-07-27 | Abbott Laboratories | Viral inactivation during purification of antibodies |
| TWI610936B (zh) | 2008-10-20 | 2018-01-11 | 艾伯維有限公司 | 使用蛋白質ａ親和性層析進行抗體之分離及純化 |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US20120178910A1 (en) * | 2009-09-23 | 2012-07-12 | Medarex, Inc. | Cation exchange chromatography (methods) |
| AR080244A1 (es) * | 2010-02-23 | 2012-03-21 | Genentech Inc | Terapia anti-angiogenesis para el tratamiento del cancer ovarico |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| SG184195A1 (en) | 2010-03-30 | 2012-11-29 | Janssen Biotech Inc | Humanized il-25 antibodies |
| LT3351636T (lt) | 2010-05-14 | 2020-10-12 | Oregon Health & Science University | Rekombinantiniai žcmv ir rhcmv vektoriai koduojami heterologiniu antigenu, išskirtu iš paramyxoviridae viruso ir jų panaudojimas |
| AU2011258254B2 (en) * | 2010-05-25 | 2016-01-07 | Genentech, Inc. | Methods of purifying polypeptides |
| GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
| JP5838221B2 (ja) * | 2010-12-21 | 2016-01-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | アイソフォーム濃縮抗体調製物及びこれを得る方法 |
| MY162570A (en) * | 2011-03-29 | 2017-06-30 | Glaxosmithkline Llc | Buffer system for protein purification |
| EP2714713B1 (en) * | 2011-05-26 | 2018-05-09 | Dr. Reddy's Laboratories Limited | Purification of anti-cd20 antibodies |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| WO2013054250A1 (en) * | 2011-10-10 | 2013-04-18 | Dr Reddy's Laboratories Limited | Purification method |
| HUE044352T2 (hu) | 2011-10-14 | 2019-10-28 | Hoffmann La Roche | Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére |
| RU2478646C1 (ru) * | 2011-11-28 | 2013-04-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения высокоаффинных поликлональных антител |
| CA2859376C (en) | 2011-12-22 | 2022-04-19 | Genentech, Inc. | Use of ion exchange chromatography for improving downstream chromatography steps for purification of antibodies |
| LT2872534T (lt) | 2012-07-13 | 2018-10-25 | Roche Glycart Ag | Dvigubai specifiniai anti-vegf/anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
| JP6253584B2 (ja) * | 2012-08-27 | 2017-12-27 | 旭化成メディカル株式会社 | 温度応答性クロマトグラフィーによる抗体の精製方法 |
| CN103217499B (zh) * | 2013-01-15 | 2015-12-02 | 珠海市丽珠单抗生物技术有限公司 | 一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法 |
| SG10202011130TA (en) | 2013-03-08 | 2020-12-30 | Genzyme Corp | Continuous purification of therapeutic proteins |
| UY35517A (es) * | 2013-04-04 | 2014-10-31 | Mabxience S A | Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína |
| AR095863A1 (es) | 2013-04-16 | 2015-11-18 | Genentech Inc | Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación |
| WO2015064971A1 (ko) * | 2013-10-30 | 2015-05-07 | (주)셀트리온 | 양이온 교환 크로마토그래피를 이용한 항체의 아형 분리 방법 |
| CN104628846B (zh) * | 2013-11-06 | 2019-12-06 | 三生国健药业（上海）股份有限公司 | 重组蛋白质的纯化方法 |
| JP6529188B2 (ja) | 2013-11-25 | 2019-06-12 | シアトル ジェネティックス， インコーポレイテッド | コンジュゲーションのためのｃｈｏ細胞培養物からの抗体の調製 |
| TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
| TWI671312B (zh) | 2014-01-17 | 2019-09-11 | 美商健臻公司 | 無菌層析法及製法 |
| US20160347787A1 (en) | 2014-02-04 | 2016-12-01 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| SI3116891T1 (sl) | 2014-03-10 | 2020-07-31 | Richter Gedeon Nyrt. | Čiščenje imunoglobulina z uporabo predčistilnih stopenj |
| CN105017418B (zh) * | 2014-03-27 | 2021-02-23 | 上海药明康德新药开发有限公司 | 单克隆抗体纯化工艺方法 |
| KR20160141857A (ko) | 2014-04-25 | 2016-12-09 | 제넨테크, 인크. | 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법 |
| KR102403547B1 (ko) | 2014-07-16 | 2022-05-30 | 오레곤 헬스 앤드 사이언스 유니버시티 | 외인성 항원을 포함하는 인간 시토메갈로바이러스 |
| CN105315369B (zh) * | 2014-07-25 | 2020-03-13 | 山东博安生物技术有限公司 | 利用阳离子交换层析纯化蛋白质 |
| EA035635B1 (ru) * | 2015-03-13 | 2020-07-17 | Бристол-Маерс Сквибб Компани | Использование щелочных промывочных растворов во время хроматографии для удаления примесей |
| SI3302551T1 (sl) | 2015-05-30 | 2024-10-30 | F. Hoffmann-La Roche Ag | Metode zdravljenja predhodno nezdravljenega her2-pozitivnega metastatskega raka dojk |
| KR101657690B1 (ko) * | 2015-06-05 | 2016-09-19 | 주식회사 녹십자홀딩스 | 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법 |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| AU2016355468B2 (en) | 2015-11-20 | 2022-12-15 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| GB201600512D0 (en) | 2016-01-12 | 2016-02-24 | Univ York | Recombinant protein production |
| CA3019426A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| US10654922B2 (en) * | 2016-05-13 | 2020-05-19 | Askgene Pharma Inc. | Angiopoietin 2, VEGF dual antagonists |
| JP7177035B2 (ja) * | 2016-07-15 | 2022-11-22 | エフ．ホフマン－ラ ロシュ アーゲー | Ｐｅｇ化エリスロポエチンを精製するための方法 |
| CN106222222B (zh) * | 2016-08-08 | 2019-10-29 | 湖北医药学院 | 一种重组人白血病抑制因子的制备方法 |
| WO2018045587A1 (zh) * | 2016-09-12 | 2018-03-15 | 广东东阳光药业有限公司 | 一种抗vegf类单克隆抗体的纯化方法 |
| CN106380519B (zh) * | 2016-10-17 | 2019-11-01 | 深圳万乐药业有限公司 | 一种单克隆抗体的纯化方法 |
| PE20190840A1 (es) | 2016-10-18 | 2019-06-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e |
| WO2018078158A1 (en) * | 2016-10-31 | 2018-05-03 | Hexal Ag | Antibody preparation |
| KR102313262B1 (ko) | 2016-12-28 | 2021-10-14 | 제넨테크, 인크. | 진행성 her2 발현 암의 치료 |
| WO2018136412A2 (en) | 2017-01-17 | 2018-07-26 | Genentech, Inc. | Subcutaneous her2 antibody formulations |
| WO2018160654A2 (en) | 2017-03-02 | 2018-09-07 | Genentech, Inc. | Adjuvant treatment of her2-positive breast cancer |
| BE1025090B1 (fr) | 2017-03-30 | 2018-10-29 | Univercells Sa | Procede et kit de purification de proteines |
| AR111465A1 (es) * | 2017-04-14 | 2019-07-17 | Cj Healthcare Corp | Método para la purificación de anticuerpos análogos por el uso de cromatografía de intercambio de cationes |
| JP2020517273A (ja) | 2017-04-24 | 2020-06-18 | ジェネンテック， インコーポレイテッド | 膜貫通ドメインまたは膜近傍ドメインにおけるＥｒｂＢ２／Ｈｅｒ２突然変異 |
| MX2019015304A (es) | 2017-06-21 | 2020-02-17 | Cephalon Inc | Amortiguador de lavado para cromatografia de intercambio cationico. |
| MA50195A (fr) * | 2017-09-22 | 2020-07-29 | Immunogen Inc | Séparation d'anticorps à chaîne triple légère à l'aide d'une chromatographie à échange de cations |
| CN110272491B (zh) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体的纯化工艺 |
| US20210009632A1 (en) * | 2018-03-29 | 2021-01-14 | Bristol-Myers Squibb Company | Methods of purifying monomeric monoclonal antibodies |
| WO2019217570A1 (en) * | 2018-05-08 | 2019-11-14 | Waters Technologies Corporation | Methods, compositions and kits useful for ph gradient cation exchange chromatography |
| BR112021003420A2 (pt) | 2018-08-31 | 2021-05-18 | Genzyme Corporation | resina cromatográfica estéril e uso da mesma em processos de manufatura |
| EP3643322A1 (en) * | 2018-10-26 | 2020-04-29 | Mabion SA | Low aggregate anti cd20 ligand formulation |
| CN109320611B (zh) * | 2018-10-31 | 2022-06-03 | 鼎康(武汉)生物医药有限公司 | 一种人鼠嵌合单克隆抗体生物类似药的纯化方法 |
| CN112206327A (zh) * | 2019-07-12 | 2021-01-12 | 上海药明生物技术有限公司 | 一种抗体偶联药物的制备及其高通量筛选方法 |
| CN114599971A (zh) * | 2019-10-14 | 2022-06-07 | 皮尔斯生物科技有限公司 | 肽纯化配制物和方法 |
| CA3162748A1 (en) * | 2019-11-25 | 2021-06-03 | Akeso Biopharma, Inc. | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof |
| KR102153258B1 (ko) * | 2020-02-21 | 2020-09-07 | 프레스티지바이오로직스 주식회사 | 베바시주맙 정제의 최적화된 방법 |
| US11416468B2 (en) * | 2020-07-21 | 2022-08-16 | International Business Machines Corporation | Active-active system index management |
| CN114591438B (zh) * | 2022-04-25 | 2023-12-05 | 达石药业(广东)有限公司 | 一种采用阳离子交换层析法纯化双特异性抗体的方法 |
| WO2024090489A1 (ja) * | 2022-10-26 | 2024-05-02 | 日本メジフィジックス株式会社 | 放射性医薬組成物の製造方法 |
| CN115850493B (zh) * | 2022-11-08 | 2024-03-12 | 江苏耀海生物制药有限公司 | 一种二价纳米抗体Cablivi的分离纯化方法 |
| CN117756878A (zh) * | 2023-12-26 | 2024-03-26 | 康日百奥生物科技(苏州)有限公司 | 抗体层析分离方法及应用 |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
| GB2070818A (en) | 1980-02-04 | 1981-09-09 | Philips Electronic Associated | Regulated power supply for an image intensifier |
| WO1984002129A1 (en) | 1982-11-22 | 1984-06-07 | Takeda Chemical Industries Ltd | Human immune interferon protein and process for its preparation |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
| WO1986002068A1 (en) | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Mutual separation of proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US5196323A (en) | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| CA1283072C (en) * | 1986-12-01 | 1991-04-16 | Timothy Durance | Process for the isolation and separation of lysozyme and avidin from eggwhite |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5451662A (en) * | 1987-10-23 | 1995-09-19 | Schering Corporation | Method of purifying protein |
| US5118796A (en) | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| IT1219874B (it) | 1988-03-18 | 1990-05-24 | Fidia Farmaceutici | Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche |
| US5115101A (en) * | 1988-06-08 | 1992-05-19 | Miles Inc. | Removal of protein A from antibody preparations |
| WO1989012463A1 (en) | 1988-06-21 | 1989-12-28 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5112951A (en) * | 1989-07-28 | 1992-05-12 | Hybritech Incorporated | Separation of anti-metal chelate antibodies |
| US5110913A (en) | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
| EP0467466A1 (en) * | 1990-07-16 | 1992-01-22 | Eastman Kodak Company | Method for the purification of immunoreactive labeled thyroxine conjugates |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| ATE233813T1 (de) | 1991-08-14 | 2003-03-15 | Genentech Inc | Veränderte immunglobuline für spezifische fc- epsilon rezeptoren |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| JPH05202098A (ja) | 1992-01-29 | 1993-08-10 | Snow Brand Milk Prod Co Ltd | 乳質原料から生理活性物質の製造法 |
| EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
| US5279823A (en) | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
| EP0656789B1 (en) | 1992-08-21 | 1997-12-17 | Genentech, Inc. | Method for treating a lfa-1-mediated disorder |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| RU2139731C1 (ru) | 1992-11-13 | 1999-10-20 | Айдек Фармасьютикалс Корпорейшн (US | Способ лечения, антитела, гибридома |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| WO1995016203A2 (en) | 1993-12-10 | 1995-06-15 | Genentech, Inc. | Methods for diagnosis of allergy and screening of anti-allergy therapeutics |
| WO1995019181A1 (en) | 1994-01-18 | 1995-07-20 | Genentech, Inc. | A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| EP0749488A1 (en) | 1994-03-03 | 1996-12-27 | Genentech, Inc. | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ATE222774T1 (de) | 1996-01-23 | 2002-09-15 | Genentech Inc | Antikörper gegen cd 18 zur verwendung gegen gehirnschlag |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| DE69738074T2 (de) * | 1996-11-15 | 2008-05-21 | Genentech, Inc., South San Francisco | Reinigung von neurotrophinen |
| WO1998023761A1 (en) | 1996-11-27 | 1998-06-04 | Genentech, Inc. | HUMANIZED ANTI-CD11a ANTIBODIES |
| DE69739673D1 (de) | 1996-11-27 | 2009-12-31 | Genentech Inc | Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| CN1191276C (zh) | 1997-04-07 | 2005-03-02 | 基因技术股份有限公司 | 人源化抗体和制备人源化抗体的方法 |
| CN100480269C (zh) | 1997-04-07 | 2009-04-22 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
| IL132067A0 (en) | 1997-05-15 | 2001-03-19 | Genentech Inc | Apo-2 receptor |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| ES2198913T5 (es) | 1998-05-06 | 2013-11-18 | Genentech, Inc. | Purificación de proteínas mediante cromatografía de intercambio iónico |
| DE69919701T2 (de) | 1998-06-01 | 2005-09-15 | Genentech, Inc., South San Francisco | Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie |
| ES2229784T3 (es) | 1998-06-09 | 2005-04-16 | Statens Serum Institut | Proceso de produccion de inmunoglobulinas para administracion intravenosa y otros productos de inmunoglobulina. |
| CH694589A5 (de) | 1999-06-25 | 2005-04-15 | Genentech Inc | Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern. |
| IL149116A0 (en) | 1999-10-29 | 2002-11-10 | Genentech Inc | Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| US6417355B1 (en) | 2001-04-11 | 2002-07-09 | The United States Of America As Represented By The Secretary Of The Navy | Geminal-dinitro-1-5 diazocine derivatives |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| US6770027B2 (en) * | 2001-10-05 | 2004-08-03 | Scimed Life Systems, Inc. | Robotic endoscope with wireless interface |
| EP1507793A4 (en) | 2001-10-17 | 2006-02-01 | Human Genome Sciences Inc | NEUTROKIN ALPHA AND NEUTROKIN ALPHA SPLICE VERSION |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| JP4498746B2 (ja) | 2002-02-14 | 2010-07-07 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ２０抗体およびその融合タンパク質ならびに使用法 |
| US20060182740A1 (en) * | 2002-06-21 | 2006-08-17 | Biogen Idec, Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| JP5303092B2 (ja) * | 2002-09-11 | 2013-10-02 | ジェネンテック， インコーポレイテッド | タンパク質精製 |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| MXPA05006306A (es) | 2002-12-13 | 2005-09-21 | Mitra Medical Technology Ab | Agentes de direccionamiento antilinfoma con funciones efectoras y de afinidad enlazados a traves de un reactivo trifuncional. |
| PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| NZ554885A (en) | 2002-12-31 | 2009-07-31 | Altus Pharmaceuticals Inc | Complexes of hgh crystals and protamine polymers |
| WO2004087761A1 (ja) * | 2003-03-31 | 2004-10-14 | Kirin Beer Kabushiki Kaisha | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
| CN1802388B (zh) | 2003-05-09 | 2011-01-05 | 杜克大学 | Cd20特异抗体及使用它们的方法 |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| US20050079184A1 (en) | 2003-08-08 | 2005-04-14 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| KR100524074B1 (ko) | 2003-10-01 | 2005-10-26 | 삼성전자주식회사 | 베젤 구조를 가지는 전자기기 |
| TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| US20060002930A1 (en) * | 2004-04-16 | 2006-01-05 | Genentech, Inc. | Treatment of disorders |
| CN101022829A (zh) * | 2004-04-16 | 2007-08-22 | 健泰科生物技术公司 | 用抗cd20抗体治疗多软骨炎和多发性单神经炎 |
| WO2006069403A2 (en) * | 2004-12-22 | 2006-06-29 | Genentech, Inc. | Methods for producing soluble multi-membrane-spanning proteins |
| KR101660575B1 (ko) * | 2005-03-11 | 2016-09-27 | 와이어쓰 엘엘씨 | 약한 분배성 크로마토그래피법 |
| TW200740839A (en) * | 2005-06-17 | 2007-11-01 | Wyeth Corp | Methods of purifying Fc region containing proteins |
| US8246983B2 (en) * | 2005-09-02 | 2012-08-21 | Northwestern University | Encapsulated arsenic drugs |
| KR20080111487A (ko) * | 2006-03-20 | 2008-12-23 | 메다렉스, 인코포레이티드 | 단백질 정제 방법 |
| US7863426B2 (en) * | 2006-04-05 | 2011-01-04 | Abbott Biotechnology Ltd. | Antibody purification |
| FI2061803T4 (fi) * | 2006-08-28 | 2023-03-14 | Process for the purification of fc-containing proteins | |
| US8620738B2 (en) | 2006-08-31 | 2013-12-31 | Visa U.S.A. Inc | Loyalty program incentive determination |
| US20110130544A1 (en) * | 2007-03-30 | 2011-06-02 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
| BRPI0817182A2 (pt) * | 2007-10-30 | 2015-03-17 | Genentech Inc | Método para purificar um anticorpo e composições |
| US9813410B2 (en) | 2014-06-26 | 2017-11-07 | Rakuten, Inc. | Information processing apparatus, information processing method, and information processing program |
-
2008
- 2008-10-29 BR BRPI0817182 patent/BRPI0817182A2/pt not_active Application Discontinuation
- 2008-10-29 KR KR1020147036127A patent/KR20150008503A/ko not_active Application Discontinuation
- 2008-10-29 EP EP08844379.1A patent/EP2215117B2/en active Active
- 2008-10-29 SI SI200831381T patent/SI2215117T2/en unknown
- 2008-10-29 PL PL14189095T patent/PL2840090T3/pl unknown
- 2008-10-29 TW TW103117553A patent/TWI554517B/zh active
- 2008-10-29 CN CN201510941252.9A patent/CN105315323A/zh active Pending
- 2008-10-29 HU HUE08844379A patent/HUE024877T2/en unknown
- 2008-10-29 SI SI200831634A patent/SI2565206T1/sl unknown
- 2008-10-29 MX MX2010004740A patent/MX2010004740A/es active IP Right Grant
- 2008-10-29 KR KR1020107011765A patent/KR101241486B1/ko active IP Right Grant
- 2008-10-29 AR ARP080104725A patent/AR069097A1/es active IP Right Grant
- 2008-10-29 TW TW097141614A patent/TWI448330B/zh active
- 2008-10-29 PL PL12189190T patent/PL2565206T3/pl unknown
- 2008-10-29 PT PT88443791T patent/PT2215117E/pt unknown
- 2008-10-29 JP JP2010532193A patent/JP5237382B2/ja active Active
- 2008-10-29 RS RS20150156A patent/RS53850B2/sr unknown
- 2008-10-29 US US12/260,623 patent/US20090148435A1/en not_active Abandoned
- 2008-10-29 RU RU2010121816/10A patent/RU2498991C2/ru active
- 2008-10-29 CA CA2703279A patent/CA2703279C/en active Active
- 2008-10-29 SI SI200831945T patent/SI2840090T1/en unknown
- 2008-10-29 ME MEP-2015-34A patent/ME02101B/me unknown
- 2008-10-29 PE PE2008001848A patent/PE20091434A1/es active IP Right Grant
- 2008-10-29 DK DK12189190.7T patent/DK2565206T3/en active
- 2008-10-29 NZ NZ584839A patent/NZ584839A/en unknown
- 2008-10-29 DK DK14189095.4T patent/DK2840090T3/en active
- 2008-10-29 HU HUE12189190A patent/HUE027668T2/en unknown
- 2008-10-29 HU HUE14189095A patent/HUE037409T2/hu unknown
- 2008-10-29 CL CL2008003218A patent/CL2008003218A1/es unknown
- 2008-10-29 SG SG2011073087A patent/SG175597A1/en unknown
- 2008-10-29 WO PCT/US2008/081516 patent/WO2009058812A1/en active Application Filing
- 2008-10-29 SG SG10201401690XA patent/SG10201401690XA/en unknown
- 2008-10-29 CN CN200880119331XA patent/CN101889025B/zh active Active
- 2008-10-29 PL PL08844379T patent/PL2215117T5/pl unknown
- 2008-10-29 ES ES08844379.1T patent/ES2533266T5/es active Active
- 2008-10-29 DK DK08844379.1T patent/DK2215117T4/en active
- 2008-10-29 KR KR1020127028627A patent/KR20140015166A/ko not_active Application Discontinuation
- 2008-10-29 AU AU2008318865A patent/AU2008318865B2/en active Active
- 2008-10-29 CN CN201310495290.7A patent/CN103554215B/zh active Active
- 2008-10-29 ES ES12189190.7T patent/ES2572958T3/es active Active
- 2008-10-29 EP EP12189190.7A patent/EP2565206B1/en active Active
- 2008-10-29 EP EP14189095.4A patent/EP2840090B1/en active Active
- 2008-10-29 EP EP18151178.3A patent/EP3441402A1/en not_active Withdrawn
- 2008-10-29 ES ES14189095.4T patent/ES2666170T3/es active Active
-
2010
- 2010-04-22 ZA ZA2010/02850A patent/ZA201002850B/en unknown
- 2010-04-25 IL IL205310A patent/IL205310A0/en unknown
- 2010-05-21 CO CO10061141A patent/CO6280422A2/es active IP Right Grant
- 2010-10-28 HK HK13109765.9A patent/HK1182401A1/zh unknown
- 2010-10-28 HK HK10110121.9A patent/HK1143821A1/xx active IP Right Maintenance
-
2011
- 2011-03-23 ZA ZA2011/02169A patent/ZA201102169B/en unknown
-
2013
- 2013-03-21 JP JP2013059102A patent/JP2013173747A/ja not_active Withdrawn
- 2013-06-03 PH PH12013501128A patent/PH12013501128A1/en unknown
-
2014
- 2014-09-30 IL IL234901A patent/IL234901A0/en unknown
- 2014-09-30 IL IL234902A patent/IL234902A0/en unknown
- 2014-11-03 US US14/531,880 patent/US9896478B2/en active Active
-
2015
- 2015-02-19 JP JP2015030881A patent/JP2015155406A/ja not_active Withdrawn
- 2015-02-19 JP JP2015030880A patent/JP5885864B2/ja active Active
- 2015-03-12 HR HRP20150282TT patent/HRP20150282T4/hr unknown
- 2015-03-19 CY CY20151100275T patent/CY1116129T1/el unknown
- 2015-06-18 IL IL239495A patent/IL239495B/en not_active IP Right Cessation
- 2015-07-28 HK HK15107237.1A patent/HK1206753A1/xx unknown
-
2016
- 2016-07-12 JP JP2016137986A patent/JP2017019790A/ja active Pending
- 2016-08-08 HK HK16109407.0A patent/HK1221234A1/zh unknown
-
2017
- 2017-12-21 US US15/850,885 patent/US20180118781A1/en not_active Abandoned
-
2018
- 2018-03-09 AR ARP180100555A patent/AR111171A2/es unknown
- 2018-06-18 HR HRP20180943TT patent/HRP20180943T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180943T1 (hr) | Pročišćavanje protutijela preko kromatografije kationske izmjene | |
| IL197053A0 (en) | Arginine wash in protein purification using affinity chromatography | |
| UA99262C2 (uk) | СПОСІБ ЗМЕНШЕННЯ КОНЦЕНТРАЦІЇ ВІЛЬНИХ Fc-ЧАСТИН В РІДИНІ, ЩО МІСТИТЬ Fc-ВМІСНИЙ БІЛОК | |
| BRPI0615026A8 (pt) | imunoglobulina de domínio variável duplo e seus usos | |
| ATE541917T1 (de) | Granulat eines sensitiven wasch- oder reinigungsmittelinhaltsstoffs | |
| IL204658A (en) | Pharmaceutical preparation for topical use in the form of an opaque gel-gel containing diclofenac diethylammonium salt | |
| DE602005013510D1 (de) | Preisgünstige Windel mit reduzierter Neigung durchzuhängen | |
| DE602006016400D1 (de) | Damit | |
| CO6290689A2 (es) | Derivados de 1,2,3,4-tetrahidropirrolo[1,2]pirazina-6-carboxamidas y de 2,3,4,5-tetrahidropirrol[1,2][1,4]-diazepina -7-carboxamidas su preparacion y su aplicacion en terapeutica | |
| BRPI0911684A2 (pt) | "composição para uso em purificação de água para uso doméstico , e , processo para purificação de água para uso doméstico | |
| RU2012127176A (ru) | Способ очистки рекомбинантного белка интерфероноподобного фактора iii типа | |
| GR20070100787A (el) | Υγρο μαγειρικο αλατι. | |
| DE502007001083D1 (de) | Sanitäre wasserleitungsarmatur mit strahlregler | |
| Osborne et al. | The response of Northern Hemisphere mid-latitude precipitation to aerosol forcing | |
| TW200742764A (en) | Soap | |
| Iyoda | Technical College in 21st Century | |
| Guo | Why the Real Economy Is More “Hollowing-out”? | |
| FR2885298B1 (fr) | Compositions cosmetiques destinees a une application topique comprenant du stearyl fumarate de sodium. | |
| DE602005002552D1 (de) | Massagevorrichtung für Stühle oder Liegemöbel | |
| BRPI1008660A2 (pt) | derivados de n-[(2-aza-biciclo[2.1.1] hex-1-il)-aril-metil]benzamida, sua preparação e sua aplicação em teraêutica | |
| TH99821S (th) | วาล์วบังคับน้ำ | |
| TH30500S1 (th) | วาล์วบังคับน้ำ | |
| TH97251S (th) | เก้าอี้นอน | |
| TH103828S (th) | ก๊อกน้ำ | |
| TH81289B (th) | อุปกรณ์ข้อต่อท่อ |